You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Choroidal Neovascular Membrane,

Showing 26 - 50 of 3,017
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neovascularization, Choroidal, Macular Degeneration, Age-Related Trial in United States (Faricimab, Ranibizumab, Sham Procedure)

Completed
Has Results
  • Neovascularization, Choroidal
  • Macular Degeneration, Age-Related
  • Phoenix, Arizona
  • +24 more
Dec 9, 2020

Central Serous Chorioretinopathy Trial in Hong Kong

Recruiting
  • Central Serous Chorioretinopathy
    • Hong Kong, Hong Kong
    • +2 more
    Apr 19, 2022

    Tumors Trial in Beijing ([68Ga]P3)

    Recruiting
    • Neoplasms
    • Beijing, Beijing, China
      Peking University First Hospital
    Jun 4, 2023

    Pachychoroid Neovasculopathy Trial (Three monthly injections of intravitreal aflibercept)

    Not yet recruiting
    • Pachychoroid Neovasculopathy
    • Three monthly injections of intravitreal aflibercept
    • (no location specified)
    Dec 14, 2022

    Wet Macular Degeneration Trial in Worldwide (Faricimab, Aflibercept, Sham Procedure)

    Completed
    Has Results
    • Wet Macular Degeneration
    • Phoenix, Arizona
    • +138 more
    Dec 16, 2022

    Neovascular Age-related Macular Degeneration Trial in Phoenix, Winter Haven, Cleveland (Placebo, LFG316)

    Terminated
    • Neovascular Age-related Macular Degeneration
    • Phoenix, Arizona
    • +2 more
    Dec 11, 2020

    Non-invasive Optical Angiography in Age-related Macular

    Recruiting
    • Age Related Macular Degeneration
    • Non-invasive OCT based optical angiography
    • +3 more
    • Vienna, Austria
      Medical University of Vienna
    Jan 13, 2023

    Wet Macular Degeneration Trial in Worldwide (Faricimab, Aflibercept, Sham Procedure)

    Completed
    Has Results
    • Wet Macular Degeneration
    • Mesa, Arizona
    • +159 more
    Apr 6, 2022

    Neovascular Age-related Macular Degeneration Trial in Suzhou (Aflibercept Ophthalmic, IBI302)

    Not yet recruiting
    • Neovascular Age-related Macular Degeneration
    • Aflibercept Ophthalmic
    • IBI302
    • Suzhou, Jiangsu, China
      Innovent Biologics (Suzhou) Co,Ltd.
    Jul 25, 2023

    Outcomes of Tolerating Subretinal Fluid in Type 1 MNV and PCV

    Recruiting
    • Polypoidal Choroidal Vasculopathy
    • +2 more
    • Intravitreal aflibercept injection
    • Seoul, Korea, Republic of
      Jae Hui Kim
    Dec 20, 2022

    CNV in AMD Analyzed by OCT Angiography Under IntravitreaL Eylea

    Active, not recruiting
    • AMD
    • Exudative Macular Degeneration
      • Bordeaux, France
      • +4 more
      Dec 2, 2022

      PIC and Its Role in Progression of Pathological Myopia

      Unknown status
      • Punctate Inner Choroidopathy
        • Tokyo, Japan
          Tokyo Medical and Dental University
        Jun 15, 2021

        Neovascular Age-related Macular Degeneration Trial in Italy (Brolucizumab)

        Recruiting
        • Neovascular Age-related Macular Degeneration
        • Ancona, AN, Italy
        • +18 more
        Aug 10, 2022

        Adaptive Optics Imaging of Outer Retinal Diseases

        Recruiting
        • Retinal Degeneration
        • +9 more
        • Adaptive optics imaging
        • Bethesda, Maryland
        • +1 more
        Apr 25, 2022

        Number of Patient Eyes That Remained on or Switched to Anti-VEGF

        Completed
        • Age-related Macular Degeneration (AMD)
        • East Hanover, New Jersey
          Novartis Investigational site
        Oct 6, 2021

        Wet Age-related Macular Degeneration Trial (SCB-420, Aflibercept)

        Withdrawn
        • Wet Age-related Macular Degeneration
        • (no location specified)
        Apr 12, 2022

        Neovascular Age-related Macular Degeneration Trial in Beijing (TAB014 Monoclonal Antibody Injection, Ranibizumab Injection

        Recruiting
        • Neovascular Age-related Macular Degeneration
        • TAB014 Monoclonal Antibody Injection
        • Ranibizumab Injection [Lucentis]
        • Beijing, China
          Peking Union Medical College Hospital
        Jul 18, 2022

        Neovascular Age-related Macular Degeneration Trial (ASKG712)

        Not yet recruiting
        • Neovascular Age-related Macular Degeneration
        • ASKG712
        • (no location specified)
        Jul 10, 2022

        Endophthalmitis, Macula Edema, Cataract Trial in Campinas (Moxifloxacin Injection)

        Completed
        • Endophthalmitis
        • +2 more
        • Moxifloxacin Injection
        • Campinas, São Paulo, Brazil
          Hospital das Clínicas da UNICAMP
        Nov 2, 2022

        Retinal Revascularization and Clinical Indicators of Neovascular

        Recruiting
        • Wet Macular Degeneration
        • Ophthalmic Drugs
        • Arendal, Agder, Norway
          Sorlandet Hospital HF
        Mar 3, 2022

        Imaging of the Angiofibrotic Switch in Neovascular AMD

        Unknown status
        • Age-related Macular Degeneration
        • Choroidal Neovascularization
        • Best-corrected Visual acuity testing (BCVA)
        • +7 more
        • Vienna, Austria
          Medical University of Vienna
        Feb 19, 2020

        Neovascular Age-Related Macular Degeneration Trial in Worldwide (Ranibizumab, Aflibercept, Port Delivery System with ranibizumab

        Suspended
        • Neovascular Age-Related Macular Degeneration
        • Capital Federal, Argentina
        • +9 more
        Nov 8, 2022

        Neovascular Age-elated Macular Degeneration (Wet AMD), Exudative Macular Degeneration Trial in United States (LFG316, Placebo)

        Completed
        • Neovascular Age-elated Macular Degeneration (Wet AMD)
        • Exudative Macular Degeneration
        • Tucson, Arizona
        • +6 more
        Dec 11, 2020

        Angioid Streaks of Macula Trial in Mykolaiv, Odessa (Intravitreal injection)

        Recruiting
        • Angioid Streaks of Macula
        • Intravitreal injection
        • Mykolaiv, Ukraine
        • +2 more
        Feb 2, 2021

        Age-Related Macular Degeneration Trial (MG-O-1002, Placebo)

        Not yet recruiting
        • Age-Related Macular Degeneration
        • (no location specified)
        May 20, 2022